This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity

This study has been completed.
Sponsor:
Collaborator:
Instituto de Salud Carlos III
Information provided by (Responsible Party):
Gerardo Gomez Moreno, Universidad de Granada
ClinicalTrials.gov Identifier:
NCT01652001
First received: July 20, 2012
Last updated: April 4, 2016
Last verified: April 2016
July 20, 2012
April 4, 2016
January 2011
January 2014   (Final data collection date for primary outcome measure)
Dry Mouth Questionnaire (DMQ) [ Time Frame: 2 weeks ]

Dry Mouth Questionnaire (DMQ) was used in order to obtain subjective information about the severity of xerostomia before and after treatment with malic acid/placebo.

Every participant answered an initial questionnaire (DMQ 1) about the symptoms related to oral dryness, before receiving a spray (1% malic acid or placebo). After two weeks of applications, patients had to answer DMQ 1 again as well as an additional questionnaire (DMQ 2) about the efficacy of the sprays. Increased DMQ scores indicate improvement of xerostomia. DMQ 1 was used to assess the initial severity of oral dryness and in particular its impact on oral function: problems when chewing, swallowing, speaking and general impact on daily life.

DMQ 1 used a 0-to-4 rating scale where 0 = "very dry" and 4 = "not dry at all." After two weeks of treatment, DMQ 1 was repeated and it was included DMQ 2.

At the end values of DMQ 1 and DMQ 2 were summed

Dry Mouth Questionnaire (DMQ) [ Time Frame: 2 weeks ]

The DMQ is used in order to obtain subjective information about the severity of xerostomia before and after treatment with malic acid/placebo.

This test contains two questionnaire:

  • An initial questionnaire (DMQ 1) about the symptoms related to oral dryness, before receiving a spray.
  • After two weeks of applications, patients had to answer DMQ 1 again as well as an additional questionnaire (DMQ 2) about the efficacy of the sprays.
Complete list of historical versions of study NCT01652001 on ClinicalTrials.gov Archive Site
Sialometries [ Time Frame: 2 weeks ]

Unstimulated and stimulated salivary flow rates were assessed in all patients. The unstimulated salivary flow rate was obtained by the spit method every 30 seconds for 15 minutes. Saliva was collected in 20 mL plastic containers, which were pre-weighted.

Stimulated whole saliva was obtained by chewing a 1 g piece of paraffin wax for six minutes. Saliva collected during the first minute was discarded, and then collected into the container every 30 seconds.

Same as current
Not Provided
Not Provided
 
Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity
Effectiveness of Malic Acid 1% in Patients With Xerostomia Induced by Drugs. Determination of Salivary Mucins and Buffering Capacity

The aim of our study was to evaluate the clinical efficacy of a topical sialogogue spray containing 1% malic acid on patients affected by xerostomia caused by drugs.

This research took the form of a double-blind, randomized clinical trial at Faculty of Dentistry of University of Granada (Spain). Participants with antidepressant-induced and antihypertensive-induce xerostomia were divided into two groups: for the first 'intervention group' a topical sialogogue spray (1% malic acid) was applied, while for the second 'control group', a placebo spray was applied; for both groups the sprays were applied on demand during two weeks. The Dry Mouth Questionnaire (DMQ) was used to evaluate xerostomia levels before and after product/placebo application. Unstimulated and stimulated salivary flows rates, before and after application, were measured.

- Patients and study Design The study was approved by the University of Granada Research Ethics Committee (Spain). All measurements and interventions were undertaken with the understanding and written consent of each participant according to Helsinki II Agreement.The study was designed as a double-blind randomized clinical trial following guidelines established by The Consort Statement (http://www.consort-statement.org/consort-statement/). All study participants were recruited from the Faculty of Dentistry of the University of Granada (Spain)at Drug Interactions in Dentistry clinical practice, between September and December 2011. Recruitment was supervised by research assistants.

All participants had a full medical history and saliva samples were collected at the Faculty of Dentistry of University of Granada (Spain) at the Pharmacological Investigation in Dentistry Research Group laboratory (CTS-654).

Sample size determination was based on the standard deviation of the main variable: the Dry Mouth Questionnaire (DMQ)was tested to determine the minimum sample size necessary to reliably confirm the hypothesis that a topical 1% malic acid sialogogue spray, combined with xylitol and fluoride, is effective for the treatment of xerostomia induced by antidepressant drugs over a two-week period. DMQ and saliva collection were measured the same day and by the same investigator.

  • Clinical Intervention Once the participants had signed the informed consent form and anamnesis had been carried out, the following question was asked to every patient: "How often do you feel dry mouth?" Available answers were: "never", "sometimes", "usually" or "always." Those who answered "usually" or "always" were considered as suffering from xerostomia. Our clinical intervention among the intervention group subjects was the delivery to the patients of a topical sialogogue, containing 1% malic acid, xylitol 10% and fluoride0.05%(Xeros Dentaid Spray©, Dentaid, Barcelona, Spain) for two weeks, whereas a control group was given a placebo with the same presentation and composition (excepting 1% malic acid). Randomization was performed using the website http://www.randomization.com, obtaining a randomization plan, which assigned participants to either the intervention group or the control group. This randomization plan was delivered to a person unrelated to the study in order to prevent both participants and researchers from identifying the product.Both sprays were transferred by foreign personnel into two identical opaque flasks(without any brand name)labeled A and B containing respectively, either 1% malic acid or placebo.A code for randomization was kept in an opaque envelope in a safe environment and opened only at the end of the study. Data were analyzed by a third party blinded to the allocation results. 1% malic acid/placebo sprays were applied on demand, with a maximum of eight doses per day. No participants left the trial.
  • Dry Mouth Questionnaire (DMQ) The DMQ, developed by Vissink et al., Gravenmade et al., van der Reijden et al. and Regelink et al. was used in order to obtain subjective information about the severity of xerostomia before and after treatment with malic acid/placebo. Every participant answered an initial questionnaire (DMQ 1) about the symptoms related to oral dryness, before receiving a spray (1% malic acid or placebo). After two weeks of applications, patients had to answer DMQ 1 again as well as an additional questionnaire (DMQ 2) about the efficacy of the sprays. Increased DMQ scores indicate improvement of xerostomia. DMQ 1 was used to assess the initial severity of oral dryness and in particular its impact on oral function: problems when chewing, swallowing, speaking and general impact on daily life.

DMQ 1 used a 0-to-4 rating scale where 0 = "very dry" and 4 = "not dry at all." After two weeks of treatment, DMQ 1 was repeated. DMQ 2 was designed to assess the impact of the spray on the symptoms of xerostomia, and was also based on a 0-to-4 rating scale where 0 = frequent restriction of oral function and 4= no restriction of oral function/no feeling of oral dryness. The effect of the frequency and duration of spray applications in the oral cavity were also registered.

- Sialometries As secondary measurements, both unstimulated and stimulated salivary flow rates were assessed in all patients. The unstimulated salivary flow rate was obtained by the spit method every 30 seconds for 15 minutes. Saliva was collected in 20 mL plastic containers, which were pre-weighted (in 0.001 g) using a precision scale. Measurements were expressed as mL/min. Stimulated whole saliva was obtained by chewing a 1 g piece of paraffin wax for six minutes. Saliva collected during the first minute was discarded, and then collected into the container every 30 seconds. Both DMQ and sialometries were always assessed at the same time of day (from 09:00 to 11:00 a.m.) to avoid any circadian variation. Before the evaluation, participants were asked not to eat, drink, smoke or brush their teeth for one hour prior to their appointment at the clinic.Time passed between the last use of the sialogogue and the salivary flow measurements was 6 hours.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
  • Xerostomia
  • Depression
  • Hypertension
  • Drug: Malic Acid
    Oral spray for application into the oral cavity
    Other Names:
    • XerosDentaid Spray
    • Flask labeled A
  • Other: Placebo
    Oral spray for application into the oral cavity
    Other Name: Flask labeled B
  • Experimental: Malic Acid 1%

    Intervention group subjects was the delivery to the patients of a topical sialogogue, containing 1% malic acid, xylitol 10% and fluoride 0.05%(Xeros Dentaid Spray©, Dentaid, Barcelona, Spain).

    Spray was transferred by foreign personnel into identical opaque flasks(without any brand name)labeled A.

    Intervention: Drug: Malic Acid
  • Placebo Comparator: Control
    Control group was given a placebo with opaque flask(without any brand name)labeled B and with the same presentation and composition than Experimental group (excepting 1% malic acid).
    Intervention: Other: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
185
January 2014
January 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Xerostomia
  • Drug consumption
  • Antidepressant and antihypertensive agents

Exclusion Criteria:

  • Systemic diseases
  • Head and neck radiotherapy
  • Intake of drugs with high xerostomizing capacity
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
 
NCT01652001
Xerostomia-2012
PI10/00932 ( Other Grant/Funding Number: Instituto de Salud Carlos III )
Yes
Not Provided
Plan to Share IPD: No
Gerardo Gomez Moreno, Universidad de Granada
Universidad de Granada
Instituto de Salud Carlos III
Principal Investigator: Gerardo Gómez-Moreno, Professor Universidad de Granada
Universidad de Granada
April 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP